No Data
No Data
Dong-E-E-Jiao Forecasts Up to 43% Rise in H1 Profit
Dong-E-E-Jiao (SHE:000423) forecasts its attributable net profit will rise 31% to 43% to between 695 million yuan and 760 million yuan in the first half from 531.1 million yuan in the year-ago period.
Chinare Pharma (03320.HK): Dong-E-E-Jiao's net income for the first half of the year is expected to increase by 31% to 43% year-on-year.
On July 12th, Guolonghui reported that Chinares Pharma (03320.HK) released an announcement that on July 11, 2024, Dong-E-E-Jiao (000423.SZ) announced its performance forecast for the half year ended June 30, 2024. Accordingly, its net income attributed to Dong-E-E-Jiao's shareholders for the six months ended June 30, 2024 is expected to be approximately RMB 695 million to RMB 760 million, an increase of about 31% to 43% compared to the same period last year of about RMB 531.1136 million after deducting non-recurring gains and losses, and the net income is expected to be approximately RMB 658 million.
Express News | China Resources Pharmaceutical - Dong-E-E-Jiao Sees Hy Net Profit Attributable to Range From Approximately RMB695 Mln to RMB760 Mln
CHINARES PHARMA: ANNOUNCEMENTRESULTS ESTIMATE OF DONG-E-E-JIAOFOR THE SIX MONTHS ENDED 30 JUNE 2024
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
No Data